Chemical function-based pharmacophore development for novel, selective kappa opioid receptor agonists

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Computational Chemistry

Background:

• Opioid analgesics can cause central nervous system side effects.
• Developing peripherally acting opioid receptor agonists is a key strategy to mitigate these effects.
• Selective kappa opioid receptor (KOP) agonists acting peripherally are of significant interest.

Purpose of the Study:

• To develop a quantitatively predictive pharmacophore model for selective kappa opioid receptor agonists.
• To identify novel compounds with limited central nervous system access for peripheral pain management.

Main Methods:

• Utilized the HypoGen algorithm within Catalyst software.
• Developed a chemical function-based pharmacophore model using a training set of 26 KOP agonists.
• Validated the model through internal and external testing.

Main Results:

• The best pharmacophore model identified four key features: hydrophobic (HYD), ring aromatic (RA), hydrogen bond acceptor (HBA), and positive ionizable (PI).
• The model demonstrated strong predictive power through rigorous validation.
• The generated pharmacophore serves as a tool for virtual screening.

Conclusions:

• The developed Catalyst pharmacophore model is effective for identifying novel, selective KOP agonists.
• This approach facilitates the discovery of peripherally acting analgesics with reduced central side effects.
• Future applications include targeted pain treatment through peripheral mechanisms.